SYRE
Spyre TherapeuticsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Operating peers and competitors
Source-backed product markets and frozen research comparisons. Valuation comparators remain in the existing peer table.
Loading market evidence...
Research comparisons do not establish forecast usefulness or trading returns.
Compare shared product markets
Membership only; no portfolio weights or estimated losses.
+
Peers tracked
10
U.S. public peers
Grade Position
Below peers
vs peer average
SYRE vs peer average
15/100
SYRE vs. peer average (F vs. B)
Grade spread
A 4 · B 1 · C 2 · D 2 · F 1
Graded peers loaded
Coverage
10 graded
100% of tracked
Peer overview
NTLA is the first available peer comparator.
Genome-editing therapeutics company with binary clinical catalysts and elevated event-driven volatility—relevant for risk‑premium assessment.
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
SYRE
Spyre Therapeutics
NTLA
Intellia Therapeutics
Grade
F
A
Momentum
77
51
Value
41
41
Sentiment
14
83
Setup Bias
Net —
-
Market Cap
-
-
Posture
Defensive
Constructive
Grade position vs NTLA
SYRE / NTLA
Grade Position
Below peers
SYRE vs. peer average (F vs. B)
15/100
Momentum
77
SYREValue
41
SYRESentiment
14
NTLARotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs SYRE
NTLA is the first peer returned for this comparison set.